Ribomunil

Immunomodulator of bacterial origin. Ribomunil is a ribosomal-proteoglycan complex, which includes the most common pathogens of infections of the ENT organs and respiratory tract, and refers to the stimulators of specific and nonspecific immunity.

Indications Ribomunil

• prevention and treatment of recurrent infections of ENT organs (otitis, rhinitis, sinusitis, pharyngitis, laryngitis, sore throat) and respiratory tract (chronic bronchitis, tracheitis, pneumonia, infection-dependent bronchial asthma) in patients older than 6 months;
• prevention of recurrent infections in patients of risk groups (frequent and long-term sick, before the beginning of the autumn-winter season, especially in environmentally unfavorable regions, patients with chronic diseases of ENT organs, chronic bronchitis, bronchial asthma, including children older than 6 months and elderly people).

Release form

Round, biconvex, white or almost white, odorless tablets.

	1 tablet (1/3 of the dose)
Bacterial ribosomes titrated to 70% ribonucleic acid	250 mcg,
including Klebsiella pneumoniae ribosomes	3.5 shares
Streptococcus pneumoniae ribosomes	3.0 shares
Streptococcus pyogenes ribosomes	3.0 shares
Haemophilus influenzae ribosomes	0.5 of a fraction
membrane proteoglycans Klebsiella pneumoniae	375 mcg (15 fractions)

Excipients: hydrophobic colloidal silicon, magnesium stearate, sorbitol.

12 pcs. - blisters (1) - carton packs.

Round, biconvex, white or almost white, odorless tablets.

	1 tablet (1 dose)
Bacterial ribosomes titrated to 70% ribonucleic acid	750 mcg,
including Klebsiella pneumoniae ribosomes	3.5 shares
Streptococcus pneumoniae ribosomes	3.0 shares
Streptococcus pyogenes ribosomes	3.0 shares
Haemophilus influenzae ribosomes	0.5 of a fraction
membrane proteoglycans Klebsiella pneumoniae	1.125 mg (15 fractions)

Excipients: hydrophobic colloidal silicon, magnesium stearate, sorbitol.

4 pcs. - blisters (1) - carton packs.

Granules for preparation of solution for oral administration white, odorless.

	1 pac.
Bacterial ribosomes titrated to 70% ribonucleic acid	750 mcg,
including Klebsiella pneumoniae ribosomes	3.5 shares
Streptococcus pneumoniae ribosomes	3.0 shares
Streptococcus pyogenes ribosomes	3.0 shares
Haemophilus influenzae ribosomes	0.5 of a fraction
membrane proteoglycans Klebsiella pneumoniae	1.125 mg (15 fractions)

Excipients: polyvidone, mannitol (D-mannitol).

Combined material sachets (4) - carton packs.

Pharmacodynamics

The ribosomes included in the preparation contain antigens identical to the surface antigens of bacteria, and when they enter the body, they cause the formation of specific antibodies to these pathogens (vaccine effect). Membrane proteoglycans stimulate nonspecific immunity, which is manifested by increased phagocytic activity of macrophages and polynuclear leukocytes, increasing factors of nonspecific resistance. The drug stimulates the function of T- and B-lymphocytes, production of serum and secretory immunoglobulins such as IgA, interleukin-1, as well as alpha- and gamma-interferons. This explains the preventive effect of Ribomunil in relation to respiratory viral infections.

The use of Ribomunil in complex therapy can increase the effectiveness and shorten the duration of treatment, significantly reduce the need for antibiotics, bronchodilators, increase the remission period.

Pharmacokinetics

Data on pharmacokinetics of the drug Ribomunil are not provided.

Dosing and administration

Adults and children over 6 months of age are administered the drug 1 time/day in the morning on an empty stomach.

The single dose (regardless of age) is 3 tablets of 0.25 mg (with 1/3 of the single dose), 1 tablet of 0.75 mg (with one dose), or granules from 1 sachet, pre-dissolved with boiled water at room temperature.

In the first month of treatment and/or for prophylactic purposes Ribomunil is taken daily on the first 4 days of each week for 3 weeks. In the following 2-5 months - the first 4 days of each month.

In young children, the drug is recommended to be administered in the form of granules.

It is recommended to carry out three-month preventive courses of treatment 2 times a year, six-month preventive courses - once a year.

Use in children

It is used in children over 6 months of age.

Use Ribomunil during pregnancy

No special studies on the safety and efficacy of Ribomunil in pregnancy and lactation have been conducted.

The use of Ribomunil in pregnancy and during lactation (breastfeeding) is possible only after assessment of the expected benefit to the mother and the potential risk to the fetus and child.

Contraindications

• autoimmune diseases;
• hypersensitivity to the drug.

Side effects Ribomunil

Observed rarely, does not require withdrawal of the drug, characterized by:

• transient hypersalivation at the beginning of treatment, nausea, vomiting, diarrhea.
• allergic reactions (urticaria, angioedema).

Overdose

At present, no cases of overdose of the drug Ribomunil have been reported.

Interactions with other drugs

To date, no clinically significant drug interaction of the drug Ribomunil has been described.

Ribomunil can be combined with other medicines (antibiotics, bronchodilators, anti-inflammatory drugs).

Storage conditions

The drug should be stored out of reach of children and transported (by all types of covered transport) at temperatures from 15° to 25°C.

Special instructions

Patients should be warned about the possibility of transient increase in body temperature on 2-3 days, which is a manifestation of therapeutic effect of the drug and does not require, as a rule, discontinuation of treatment. Fever may sometimes be accompanied by minor and transient symptoms of infections of ENT organs.

Shelf life

The shelf life is 3 years.